← Back to headlines
Propanc Biopharma Reports Promising Preclinical Pancreatic Cancer Data
Propanc Biopharma announced compelling preclinical results for its drug candidate PRP, demonstrating over 90% tumor growth inhibition and a significant survival benefit in pancreatic cancer models.
27 Aug, 12:30 — 27 Aug, 12:30
Related Stories
Dutch Health Agency Warns of Potentially Fatal Trump-Shaped Ecstasy Pills
1h ago
48-Year-Old Anesthesiologist Found Dead in Greek Hospital On-Call Room
3h ago
Art World Mourns Yayoi Kusama as Tributes Highlight Her Lasting Creative Legacy
4h ago
Study Reveals Hidden Arterial Calcification in Young Adults
5h ago